Observational studyHematological oncology2025
Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.
Observational study in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03199066 (The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)
Who cites it
2 citing papers in PubMed.
- Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study.Current oncology (Toronto, Ont.) · 2026Article
- Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.Hematological oncology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Primary central nervous system lymphomas (PCNSL) are rare malignancies with poor survival outcomes. The IELSG32 trial demonstrated efficacy of MATRix chemoimmunotherapy followed by autologous stem cell transplantation (auto-SCT) in PCNSL patients aged ≤ 70 years with a performance status (PS) ECOG ≤ 3. However, long-term real-world results of MATRix/auto-SCT therapy remain limited. This analysis, with a median follow-up of 52 months, aimed to evaluate the outcomes of MATRix-treated PCNSL patients in clinical practice. From 2015 to 2022, 280 PCNSL patients who received systemic therapy were identified in the NiHiL project (NCT03199066). Eighty-eight individuals treated with MATRix entered the analysis. Endpoints included efficacy and safety of induction and consolidation therapy. Seventy-eight patients who met key IELSG32 inclusion criteria (age ≤ 65 years and PS ECOG ≤ 3, or age 66-70 years and PS ECOG ≤ 2) achieved an overall response rate of 82% (complete remission rate 58%) following MATRix regimen. After median follow-up of 52 months, 4-year progression-free survival and overall survival (OS) rates were 53% and 55%, respectively. Forty-six (59%) patients completed MATRix treatment, and 32 (41%) discontinued induction therapy (15 toxicity, 11 infections, 5 progressive diseases, 1 refusal). The treatment-related mortality was 8%. Among 67 patients with responsive/stable disease, 50 underwent consolidation with whole-brain radiotherapy (WBRT, n = 13) or auto-SCT (n = 37). No significant survival differences were observed between WBRT and auto-SCT (4-year OS 84% vs. 74%, HR 0.61, 95% CI 0.16-2.29, p = 0.467). Long-term real-world outcomes of MATRix/auto-SCT therapy are comparable to IELSG32, supporting its use in younger, fit PCNSL patients. CLINICAL
trial registrationThe data in this analysis were collected in the observational Czech non-Hodgkin lymphoma registry "NiHiL" (NCT03199066).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.